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Abstract 
Leukodystrophies (LD) and genetic leukoencephalopathies (gLE) are disorders that result in white matter 
abnormalities in the central nervous system (CNS). Magnetic resonance (MR) imaging (MRI) has 
dramatically improved and systematized the diagnosis of LDs and gLEs, and in combination with specific 
clinical features, such as Addison’s disease in Adrenoleukodystrophy or hypodontia in Pol-III related or 
4H leukodystrophy, can often resolve a case with a minimum of testing. The diagnostic odyssey for the 
majority LD and gLE patients, however, remains extensive – many patients will wait nearly a decade for a 
definitive diagnosis and at least half will remain unresolved. The combination of MRI, careful clinical 
evaluation and next generation genetic sequencing holds promise for both expediting the diagnostic 
process and dramatically reducing the number of unresolved cases. Here we present a workflow detailing 
the Global Leukodystrophy Initiative (GLIA) consensus recommendations for an approach to clinical 
diagnosis, including salient clinical features suggesting a specific diagnosis, neuroimaging features and 
molecular genetic testing. We also discuss recommendations on the use of broad-spectrum next-
generation sequencing in instances of ambiguous MRI or clinical findings. We conclude with a proposal 
for systematic trials of genome-wide agnostic testing as a first line diagnostic in LDs and gLEs given the 
increasing number of genes associated with these disorders. 
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Abbreviations: LD – Leukodystrophies; gLE – Genetic leukoencephalopathy; MR – Magnetic resonance; 
MRI – Magnetic resonance imaging; GLIA – Global Leukodystrophy Initiative; CNS – Central nervous 
system; SIMD – Society for Inherited Metabolic Disorders; VWM – Vanishing white matter disease; X-
ALD – X-linked Adrenoleukodystrophy; AMN – Adrenomyeloneuropathy; 4H syndrome - 
Hypomyelination, hypodontia and hypogonadotropic hypogonadism syndrome; AGS - Aicardi-Goutières 
Syndrome; HCC - hypomyelination with congenital cataracts; CTX - Cerebrotendinous xanthomatosis; 
PMD - Pelizaeus Merzbacher disease; PMLD - Pelizaeus Merzbacher like-disease; SLS -Sjögren-
Larsson syndrome; CRMCC - Cerebroretinal microangiopathy with calcifications and cysts; Pol III – 
Polymerase III; CMV - congenital cytomegalovirus; Tay syndrome – trichothiodystrophy; MLD – 
Metachromatic Leukodystrophy; FLAIR - fluid-attenuated inversion-recovery; MRS –Magnetic resonance 
spectroscopy; CT – Computed tomography; NAA – N-acetyl aspartate; ADEM – Acute disseminated 
encephalomyelitis; NGS - Next-generation sequencing ; WES – Whole exome sequencing; WGS – 
Whole genome sequencing; P – Pathogenic; LP – Likely pathogenic; CSF - cerebrospinal fluid;  
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1. Introduction and needs assessment 
Leukodystrophies (LD) are genetic disorders affecting the white matter of the central nervous 
system (CNS) with or without peripheral nervous system involvement [1, 2]. There are over thirty 
conditions typically categorized as primary LD and a number of other heritable conditions (genetic 
leukoencephalopathies- abbreviated here as gLE) that affect the white matter of the brain [2]. Primary 
LDs are those heritable conditions of the white matter that primarily effect glial cells, while gLE are 
disorders with either primary neuronal, vascular or systemic involvement, in which the white matter 
changes are felt to be secondary [2]. Depending on the etiology of the LD or gLE, inheritance can be by 
any known mechanism: autosomal recessive, (de novo) dominant, X-linked, mitochondrially-encoded etc. 
These disorders include neonatal and adult presentations as well as the full spectrum through childhood 
and adolescence. Although individual features may vary, LDs and gLEs all share white matter 
abnormalities on imaging or pathology of the CNS, and most have motor deficits that often dominate the 
clinical picture, especially in younger individuals. 
Due to challenges in diagnosis, the true prevalence and incidence of all LDs is not yet 
established. Estimates of their combined incidence range widely, from 1 in 50,000 to 1 in 7,663 [3, 4]. 
The early recognition of LDs can be challenging as they present insidiously, heterogeneously and are 
often not considered until neuroimaging shows abnormalities. Even then, they often remain undiagnosed 
or misdiagnosed, in part due to limited knowledge about their etiology.  While advances in neuroimaging 
pattern recognition have improved diagnostic yield, curative treatments are currently limited and a 
definitive diagnosis is crucial for appropriate symptom management, prognostic and genetic counseling.  
With the increasing number of LDs and gLEs a clinician must recognize, a simplified and 
standardized approach to facilitate identification of these diseases by child neurologists and geneticists is 
needed.  The Global Leukodystrophy Initiative (GLIA) assessed clinicians’ comfort in diagnosing LDs and 
gLEs and found that, despite the fact that these clinicians are members of the Society for Inherited 
Metabolic Disorders (SIMD) or Child Neurology Society, only a minority felt comfortable with the 
neuroimaging patterns and diagnostic approaches for LD and gLE patients (Table 1).  
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With the aim of providing clinicians with a simplified approach for diagnosing LDs and gLEs, here 
we (i) review the clinical presentations of various LDs and gLEs and highlight “red-flag” sine qua non 
neurologic symptoms along with extra-neurologic features, (ii) review established diagnostic algorithms 
for MRI pattern recognition, and (iii) present a decision tree workflow for molecular testing with specific 
attention to rapid diagnosis of treatable disorders and implementation of diagnostic genetic testing. 
 
2. When to suspect a leukodystrophy or genetic leukoencephalopathy 
The LDs and gLEs are a large group of relatively heterogeneous disorders [2]. Patients typically 
present with the onset of neurologic symptoms, though some may show worsening of long-standing, and 
typically milder, symptoms.  It should be noted that some LDs and gLEs have a slow and progressive 
course, and can be mistaken for static encephalopathies unless a longitudinal view of the disease is 
taken (e.g. some hypomyelinating conditions), and a minority show slow improvement over time (e.g. LD 
caused by HEPACAM and EARS2 mutations). The vast majority, however, present with gradual or abrupt 
deterioration of CNS function. 
Most LDs and gLEs present with motor symptoms. This is in contrast with primary neuronal 
disorders, which usually present with cognitive decline and seizures - although there is often overlap 
between these symptom groups. Specific LDs and gLEs may have a typical age of onset which generally 
described as infantile (first year), late infantile (1-5 years), juvenile (5-12 years) or adolescence and 
adulthood. More typically, however, there is a spectrum of disease presentation across all age groups, 
whose presenting symptoms and specific signs change accordingly. Thus, the clinical features described 
below are broadly representative of the most typical presentations of the described disorders. 
Often patients present to the neurologist with concern for a LD or gLE based on abnormal 
neuroimaging. However, if this is not the case, there are several clinical features or “red flags” that should 
alert the clinician to the possibility of a LD or gLE. These are highlighted below in italics. Establishing a 
differential diagnosis in patients with a suspected LD or gLE will begin by identifying these clinical 
features, assessing neurologic and systemic symptoms, and then performing appropriate diagnostic 
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investigations (i.e. genetic testing).  Because patients with gLEs are not considered classic LDs but are 
often evaluated in clinics for patients with presumed inherited white matter conditions, these disorders are 
also detailed below [2]. 
3. Neurologic Features 
LDs and gLEs have significant heterogeneity in disease course and in extraneurologic 
manifestations, as well as MRI patterns. Neurologic features may be more homogenous, though the 
degree to which certain features are present may vary with the age of presentation and the specific LD or 
gLE (Table 2).  
LDs and gLEs will almost always affect the motor system. Patients may present to the clinician 
with concerns of delayed acquisition of motor milestones, stagnation of motor development or frank 
regression in motor skills. In an infant or young child, delayed motor development is more common in the 
hypomyelinating disorders, whilst motor regression is more common in the LDs with myelin destruction. 
In an older child the first symptom may be frequent falls or a clumsy gait, and in an adolescent or young 
adult, deterioration in functional skills such as sporting activities. Occasionally there is acute deterioration 
in motor skills in the context of an intercurrent illness or minor head injury; the latter can be seen in 
Vanishing White Matter disease (VWM), but can also be seen in a number of other LDs or inborn errors 
of metabolism.  
The type of motor abnormality is often informative (Table 2). Patients may have early involvement 
of the corticospinal tracts resulting in a central pattern of weakness, upper motor neuron signs such as 
spastic quadraparesis or spastic paraparesis. In some cases, deep gray nuclei involvement occurs and 
patients may present with dystonia, chorea or a mixed movement disorder. Tremor may be present but is 
often non-specific and may be multifactorial in etiology.  
Selected LDs and gLEs lead to prominent loss of cerebellar volume and may present with slowly 
progressive ataxia, in some cases as an isolated clinical finding. In many LDs and gLEs however, ataxia 
is part of a broader constellation of neurologic findings, which include prominent spasticity. For other LDs 
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and gLEs, a peripheral sensory neuropathy leading to altered proprioception and imbalance may 
contribute to alterations in gait, leading to a mixed cerebellar and sensory ataxia.   
Additional neurologic features, such as autonomic dysfunction, alterations in head circumference, 
seizures or neurobehavioral abnormalities including extreme early infantile irritability, deterioration in 
school performance, new-onset hyperactivity or a change in personality can further help refine diagnostic 
considerations (Table 2). 
 
4. Extra-Neurologic Findings 
In addition to the neurologic findings associated with LDs and gLEs, a variety of extra-neural 
features can be helpful in suspecting a specific diagnosis (Table 3).  
  
4.1 Adrenal insufficiency (Addison disease) is characteristic of only two LDs: X-linked 
adrenoleukodystrophy (X-ALD) / adrenomyeloneuropathy (AMN) and peroxisome biogenesis disorders. It 
usually presents with cutaneous hyperpigmentation, hyponatremia and more rarely hypoglycemia. 
Patients may show a prolonged recovery from general anesthesia as the first indication of adrenal 
insufficiency.  
 
4.2 Other endocrine disturbances may be detected in patients with 4H leukodystrophy (Hypomyelination, 
hypodontia and hypogonadotropic hypogonadism syndrome), including hypogonadotropic hypogonadism 
(if the patient is of age to be pubertal) as well as less frequently growth factor deficiency and 
hypothyroidism. Hypothyroidism can also be seen in Aicardi-Goutières Syndrome (AGS). Post-natal 
growth failure may be seen in Cockayne syndrome but treatment with growth hormone is relatively 
contraindicated in this disorder. A significant proportion of patients with 4H leukodystrophy present with 
short stature and there have been a few reports of growth hormone deficiency. 
  
4.3 Ophthalmologic abnormalities are noted in a number of the LDs and gLEs and findings can be quite 
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useful in restricting the differential diagnosis. Congenital cataracts are typical in hypomyelination with 
congenital cataracts (HCC), neonatal onset VWM, and some patients with peroxisome biogenesis 
disorders, whereas onset of cataracts later in childhood suggests cerebrotendinous xanthomatosis 
(CTX). Cataracts can be seen rarely in 4H leukodystrophy. Retinitis pigmentosa (and associated night 
blindness) develops in adolescent and adult patients with Refsum disease and is seen in some infants 
with peroxisome biogenesis disorders. Retinal cherry red spots are frequently seen in GM1- and GM2-
gangliosidosis and sialidosis. Optic atrophy is a common feature of LDs and gLEs, most notable in 
Canavan disease, VWM, most hypomyelinating conditions and some mitochondrial disorders. Nystagmus 
is characteristic of Pelizaeus-Merzbacher disease (PMD), Canavan disease and a significant number of 
hypomyelinating LDs. Indeed, patients with PMD, Pelizaeus-Merzbacher like disease (PMLD) and 
SOX10-related disorders have early onset or congenital nystagmus whereas patients with 4H 
leukodystrophy, Oculodentodigital dysplasia, 18q- syndrome may have nystagmus at a later age. The 
presence of retinal glistening white dots with a perifoveal distribution in a patient with ichthyosis is 
pathognomonic for Sjögren-Larsson syndrome (SLS). Retinal vascular defects are seen in cerebroretinal 
micorangiopathy with calcification and cysts (CRMCC). 
 
4.4 Cortical visual impairment can also be a late feature of many LDs and gLEs as the white matter 
disease progresses to involve the cortical visual tracts. 
  
4.5 Hypodontia and oligodontia, as well as other dental abnormalities such as delayed teeth eruption, are 
characteristic of Pol III-related or 4H leukodystrophy [5]. Dental abnormalities with enamel dysplasia are a 
feature of oculodentogidigital dysplasia [6]. In peroxisome biogenesis disorders, teeth abnormalities 
include enamel defects of the secondary teeth. In Cockayne syndrome, the typical dental abnormality is 
the propensity for cavities, which is present in the majority of patients. Enamel hypoplasia, oligodontia, 
hypodontia and abnormal shape have also been described [7].  
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4.6 Dysmorphic facial features in an infant with hypotonia and/or seizures should suggest a peroxisome 
biogenesis disorder such as Zellweger syndrome. These infants often have dolichocephaly with wide 
anterior fontanelle.  Other disorders with dysmorphic features associated with white matter abnormalities 
(often multifocal) include chromosomal abnormalities, Cohen syndrome, Costello syndrome and others. 
The development of coarsening facial features is typically seen in the lysosomal storage diseases with 
white matter involvement such as multiple sulfatase deficiency, mucopolysaccharidoses and sialic acid 
storage disease. 
  
4.7 Tendinous xanthomas, particularly prominent in the Achilles tendon, along with white matter disease 
are specific signs of CTX. 
  
4.8 Skeletal radiographic abnormalities are seen in several LDs and gLEs. Chondrodysplasia punctata is 
an early feature of the peroxisome biogenesis disorders. Development of radiographic features of 
dysostosis multiplex in a patient with white matter disease suggests multiple sulfatase deficiency or 
sialidosis.  
 
4.9 Hearing impairment may be seen as a non-specific association of many LDs and gLEs involving the 
auditory nerves, but it is rarely the presenting symptom. Sensorineural deafness is typical of peroxisome 
biogenesis disorders and may also be seen in SOX10 associated LD. It may be detected as early as the 
newborn period through routine newborn hearing screening programs, or later in infancy and childhood. 
An important diagnosis to consider in case of sensorineural deafness is congenital cytomegalovirus 
(CMV) infection, since this condition may also present with significant multifocal white matter 
abnormalities and myelin deficits. RNASET2 deficiency, is an autosomal recessive disorder that mimic 
congenital CMV and therefore should also be considered in case of sensorineural hearing deficit. Later 
onset deafness in adults occurs in Refsum disease. More commonly, the hearing impairment in LDs and 
gLEs is central in origin. 
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4.10 Hepatosplenomegaly is a feature of certain lysosomal storage diseases with white matter 
involvement including multiple sulfatase deficiency, galactosialidosis and sialic acid disorders. Isolated 
hepatomegaly with or without hepatic dysfunction is often present in peroxisome biogenesis disorders. 
Hepatic dysfunction may also be seen in the congenital period or more rarely in infancy in AGS. gLEs 
caused by mitochondrial dysfunction may have associated hepatic abnormalities. 
  
4.11 Cutaneous abnormalities are associated with several LDs and gLEs. Angiokeratomas are seen in 
galactosialidosis. Ichthyosis is a distinctive feature that is present at birth in SLS and later in childhood in 
multiple sulfatase deficiency or adults with Refsum disease. Ichthyosis with sparse, brittle hair is an 
unusual clinical finding in trichothiodystrophy (Tay syndrome) and is also associated with cutaneous 
photosensitivity. Cutaneous photosensitivity is also seen in Cockayne syndrome. Hyperpigmentation is a 
sign of adrenal insufficiency in children and adults with X-ALD/AMN. 
  
4.12 Ovarian dysgenesis and dysfunction characterizes a distinctive variant of VWM 
(ovarioleukodystrophy). Ovarian dysfunction has also been recently recognized in leukoencephalopathy 
associated with the t-RNA synthetase deficiency caused by AARS2 mutations. The primary ovarian 
failure seen in these disorders should not be confused with the hypogonadotropic hypogonadism seen in 
4H leukodystrophy. 
  
4.13 Gastrointestinal symptoms, often chronic, with diarrhea are often seen in CTX and in some patients 
with mitochondrial disorders, particularly mitochondrial neurogastrointestinal encephalopathy. 
Metachromatic Leukodystrophy (MLD) may be accompanied by severe, poorly understood feeding 
intolerance and gallbladder disease that may require cholecystectomy. Rare patients with AGS may have 
a condition mimicking inflammatory bowel disease. Many patients with LDs and gLEs have 
gastrointestinal reflux and chronic constipation which may cause significant morbidity. 
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5. Diagnostic Recommendations 
The clinical evaluation of patients with LDs and gLEs should take into account all available clinical 
information including age of onset, family history, neurologic symptoms and the presence of characteristic 
extra-neurologic features as described above. Tables 2 and 3 can be used as a template for an initial 
assessment of a patient suspected of having any of the canonical LDs. Similarly detailed phenotypic 
descriptions of the gLEs are beyond the scope of this manuscript. Any initial evaluation that indicates 
strong concordance of a patient’s presentation with that of a LD or gLE should trigger the following three 
actions, as described in detail below, which can occur in series or in parallel: (1) immediate assessment 
of the likelihood of a genetic etiology and if the putative LD or gLEs is treatable, (2) a detailed 
neuroimaging series, (3) molecular genetic testing (summarized in brief in Figure 1).  
 
5.1 Neuroimaging. Brain MRI is the foundational investigation in a patient with a suspected LD or gLE 
(Figure 1, box 1) [8-16]. The imaging findings should be interpreted in the context of the clinical and 
family history and the examination findings, but may often be diagnostic even before these elements are 
known. Following MRI interpretation, it may be possible to determine a differential diagnosis for a given 
white matter disorder using a “pattern recognition” approach (Figure 1) [1, 8].  Correct interpretation of 
clinical and imaging findings will often allow the clinician to order tailored investigations rather than 
subjecting the patient to a battery of unnecessary and expensive testing. Sagittal T1, Axial T1, T2-
weighted and fluid-attenuated inversion-recovery (FLAIR) sequences should be obtained at a minimum. 
Other sequences may also be required such as administration of contrast (for disorders with an 
inflammatory component such as cerebral X-ALD), susceptibility weighting (for disorders with 
calcifications such as AGS), MR spectroscopy (MRS)(for mitochondrial disorders or Canavan disease to 
investigate abnormalities in lactate or N-acetyl aspartate (NAA) respectively), and diffusion-weighting 
(useful in disorders such as AARS2-related leukoencephalopathy). MRI is superior to CT, although CT 
may still be helpful to detect calcifications, in particular if newer MRI techniques helpful for detecting 
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calcifications were not performed.  A spine MRI should be obtained on at least one occasion in all 
patients with an undiagnosed LD or gLE to assess for spinal cord involvement.  
A single brain MRI, especially when it is performed in the first year of life, is not sufficient to 
distinguish between delayed myelination, hypomyelination and the early stages of a LD/gLE. Therefore, 
serial MRI scans are often required, usually with a minimum of 6-12 months interval between studies. 
Ideally, at least one scan should be obtained after the age of two years. 
According to published MRI-based diagnosis algorithms [1, 8], three major MRI characteristics 
help to discriminate between the different types of LD and gLE. The first discriminator is the presence or 
absence of hypomyelination (Figure 1a) and in this regard assessment of the T1 sequences are of 
particular importance, as T1 shortening occurs before T2 shortening as myelination progresses. 
Hypomyelination is defined as an unchanged pattern of deficient myelination on two MRI scans at least 
six months apart in a child older than one year [1, 8]. Hypomyelinating disorders can be further divided 
into those with and without involvement of the cerebellum and basal ganglia, and with and without global 
atrophy.  
If the pattern is not one of hypomyelination, then the second discriminator is whether the white 
matter abnormalities are confluent or isolated and multifocal [1, 8] (Figure 1b). Multifocal changes often 
imply an acquired disorder such as infection or vasculopathy or a structural chromosomal disorder, whilst 
bilateral, symmetric confluent changes usually imply a gLE or LD. If the white matter abnormalities are 
confluent, then the third discriminator is the predominant localization of the abnormalities (Figure 1b). The 
most common patterns are frontal (e.g. Alexander disease(AxD)), parieto-occipital (e.g. X-ALD), 
periventricular (e.g. MLD), subcortical (e.g. Canavan disease), diffuse cerebral (e.g. VWM) or posterior 
fossa (e.g. peroxisomal disorders) predominant. Assessment of structures such as the cortex, basal 
ganglia, cerebellum, thalami and the descending white matter tracts is also important for further 
discrimination. Additional imaging features such as contrast enhancement, presence of calcifications, or 
macrocephaly can also help refine the diagnosis [1, 8]. Other MRI techniques, such as diffusion tensor 
imaging, spectroscopy and various multivariate analysis techniques of MRI data may be sensitive 
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indicators of involvement of certain white matter tracts or myelination but principally remain research 
tools. It should be noted that even with high quality imaging, expert imaging interpretation and a complete 
battery of clinical investigations at least 30-40% of LDs and gLEs, and 50% of hypomyelinating, cases 
remain unresolved.  
 
5.2 Special attention to disease etiology and amenability to treatment. Once an abnormal MRI is 
observed it is of primary importance to resolve etiology of the patient’s white matter disorder (Figure 1, 
box 2). Acquired and genetic white matter disorders share many imaging and phenotypic features, and in 
some cases are easily confused (and therefore may require expert evaluation – Figure 1, box 4). Failure 
to correctly identify the source of the patient’s disorder quickly can have negative consequences. For 
example, in the case of patients with acquired white matter disorders it can lead to unnecessary 
interventions and diagnostic testing, and may result in failure to identify treatable entities (Figure 1, boxes 
5 & 9). For example, acute disseminated encephalomyelitis (ADEM) can be controlled with high doses of 
corticosteroids and white matter abnormalities that result from B12 deficiency can be reversed with 
vitamin supplementation. 
In the assessment of a patient with a suspected LD or gLE, we recommend explicit and rapid 
evaluation for those disorders with established therapeutic interventions (Figure 1, boxes 3 -7 and Table 
4). These include X--ALD, Krabbe disease, and MLD, which are all rapidly diagnosable biochemically, 
and some patients may benefit from bone marrow transplantation in the early stages of the disease 
{Helman, 2014 #97}. It also includes CTX which is arguably the most easily treatable LD and responds to 
both chenodeoxycholic acid and inhibitors of HMG-CoA reductase [17]. Although beyond the scope of the 
discussion here, we also note that a variety of gLEs with significant associated white matter involvement 
are also treatable and include the amino acidemias (e.g. Maple Syrup Urine Disease, Phenylketonuria), 
organic acidurias (Methylmalonic, isovaleric and propionic acidemias, etc.), Niemann-Pick type C, 
biotinidase deficiency, and Wilson’s disease. To ensure that these disorders are not missed during work-
up we strongly recommend a minimum testing battery in all suspected LD or gLE cases consistent with 
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these disorders that assesses very long chain fatty acids, lysosomal enzymes (including 
galactocerebrosidase activity, arylsulfatase A activity, and cholestanol) and a re-evaluation of newborn 
screening test results as well as possible indications for other treatable conditions.  
 
5.3 Biochemical and molecular genetic testing. Following MRI pattern analysis, the standard diagnostic 
approach to LDs and gLEs consists of serial biochemical and single gene testing. In some cases, 
particularly for LDs and gLEs with clearly defined MRI patterns, this is an effective and timely approach 
(Figure 1, boxes 3,6,7,10). Indeed, biochemical testing is essential for reliably diagnosing many of the 
clearly defined LDs and gLEs. Measurements of lysosomal enzymes for MLD, Krabbe disease, multiple 
sulfatase deficiency, and GM1/GM2 gangliosidosis are widely available. In some cases, enzymatic 
studies must be supported by biochemical measurements showing substrate accumulation. For example, 
determination of urinary sulfatides and glycosaminoglycans provides additional evidence for the 
diagnosis of metachromatic leukodystrophy or multiple sulfatase deficiency, respectively. Additionally, 
plasma very long-chain fatty acids measurement is a sensitive screening test for ALD, peroxisome 
biogenesis disorders and peroxisomal ß-oxidation defects. Urine organic acids analysis will detect 
biochemical abnormalities of L-2-hydroxyglutaric aciduria and Canavan disease, and may reveal Krebs 
cycle intermediates suggestive of mitochondrial diseases. Lastly, plasma cholestanol levels are typically 
elevated in CTX, which is one of the most easily treated LDs and gLEs (see above and Table 4). Single 
gene tests are also available for these disorders, and can provide additional or initial validation of the 
suspected diagnosis. When successful, these biochemical and genetic investigations can take as little as 
several weeks to complete. 
For patients for whom there is no definitive MRI pattern, however, and therefore no definitive 
biochemical or single gene test, the diagnostic process may take nearly a decade [18] and will leave as 
many as half of individuals without a specific diagnosis [9]. High-throughput sequencing technologies, 
particularly gene panel-based approaches and whole exome sequencing, have now been used to identify 
the causal mutations underlying a wide variety of illnesses [19, 20]; and recent proof-of-principle studies 
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have indicated that partnering MRI pattern analysis and next-generation sequencing may lead to higher 
diagnostic yield and more timely diagnosis [21]. 
For those patients who have an abnormal but ambiguous MRI, and whose condition is clearly 
genetic, we advise broad spectrum next-generation sequencing (NGS) genetic testing using either gene 
panels, whole exome sequencing (WES) (which queries the entire coding sequence of the human 
genome), or whole genome sequencing (WGS) (Figure 1, box 8). The number of genes associated with 
LDs and gLEs continues to increase (a detailed list can be found in Table 5), and the phenotypic 
spectrum of disorders with secondary white-matter involvement continues to broaden, and it is therefore 
arguable that in many cases WES or WGS may therefore be the best near-term testing option.  
Variants detected by NGS should be analyzed and categorized according to ACMG standards 
[22]. We recommend prioritizing known pathogenic (P) or likely pathogenic (LP) variants in disease genes 
that are known to have primary or secondary white matter involvement (e.g. gLEs), which can confirmed 
by an orthogonal approach (Figure 1, box 11). We note that genetic diagnosis requires mindful return of 
information to patients and their families with appropriate genetic counseling. 
 A proportion of patients will not achieve a specific diagnosis using NGS approaches. It is likely 
that these cases will represent instances in which the pathogenic variant resides in a gene that has not 
yet been causally associated with a human disease. In those circumstances we recommend that patients 
are given the option to participate in ongoing research programs, which aggregate patients with 
undiagnosed diseases with the aim of identifying new disease genes (Figure 1, box 13). These efforts 
have proven highly successful [23, 24]. We recommend the recruitment of the patients’ mother and father 
to the study whenever possible, as sequencing of small family pedigree enables rapid identification of 
both compound heterozygous and de novo mutations. It should be taken into consideration that even with 
the ideal research conditions, causal variants are not always found, especially if the variant is located in a 
region of a gene that is not covered or not well covered, or if the type of variant is not easily detected by 
current technology (e.g. deletion, complex rearrangement). 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
5.4 Other diagnostic testing considerations. In cases where genetic testing results and other clinical 
investigations are ambiguous, we recommend consideration of additional supplementary investigations 
as detailed in Table 6. A lumbar puncture for analysis of cerebrospinal fluid (CSF) can be useful for 
evaluating a small number of LDs and gLEs. For example, CSF protein elevation is a hallmark of active 
demyelination. CSF leukocytosis, elevated interferon-α and neopterin suggest AGS. CSF NAA is 
elevated in Canavan disease, but urine organic acids testing is an equally effective diagnostic tool. In 
many cases, characterization of the neurologic disease using electrophysiologic tests, such as brainstem 
auditory-evoked potentials, sensory-evoked potentials and visual-evoked potentials can be useful. Nerve 
conduction studies and electromyography can also be useful in identifying peripheral nerve involvement 
(e.g. in AMN, MLD, Krabbe) or myopathy with or without a neuropathy (e.g. in mitochondrial diseases) or 
metachromatic leukodystrophy. 
 
6. Conclusions and future directions 
Leukodystrophies (LD), while primarily affecting the CNS, have a varied range of presentations 
with symptoms beginning at any age. Genetic Leukoencephalopathies (gLE) with white matter 
involvement and additional systemic or gray matter features, further add complexity to the diagnosis of 
these patients. Recognition of a few sine qua non “red flag” symptoms allows the clinician to astutely 
consider the LDs and gLEs in the patient’s differential diagnosis. Identifying other associated symptoms 
can help narrow the list of conditions one needs to test for. While MRI currently remains the mainstay of 
diagnosis in LDs and gLEs, in cases where the MRI pattern does not fit a specific entity, expanded 
genetic testing using NGS technologies is being used more commonly to confirm, or ab initio derive, the 
diagnosis. It is likely that future advances in genomic applications will demonstrate expanding utility to the 
early implementation of NGS testing, but this still requires trials to establish its clinical utility as a primary 
diagnostic strategy.  With advancing research, specific therapies to treat patients in the earliest stages of 
their disease are now available for some disorders, with the future hope for therapeutic options in 
additional disorders. Thus, a renewed focus on rapid recognition and diagnosis of LDs is important to 
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afford patients an opportunity for early treatment and care.  
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12. Tables 
 
 
Table 1: Clinicians’ Comfort Levels in the Diagnosis of Leukodystrophies 
 
Respondents by specialty 
Biochemical Geneticists 43% (79) 
Pediatric Neurologists 34% (62) 
Clinical Geneticists 14% (26) 
Other 9%   (16) 
Total 183  
Comfort Levels 
Very confident of providing a diagnosis [5 on a scale of 0-5] 16% 
Moderately confident of providing a diagnosis [3 or 4 on a scale of 0-5] 36% 
Very confident in providing a differential diagnosis of a leukodystrophies 15% 
Moderately confident in providing a differential diagnosis of a leukodystrophies 36% 
Access to Resources 
Access to a regional leukodystrophy expert 76% 
Cited a need for phone-based expert consult service 69% 
Reported inadequate training in leukodystrophies 57% 
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Table 2. Major neurologic signs and symptoms in the leukodystrophies- Note, if nothing is noted, these are not commonly seen features, 
though in end stage disease almost all disorders can feature the described symptoms. Disorders that are not canonical leukodystrophies (i.e. 
genetic leukoencephalopathies) are not included in this table. 
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Pol-III related disorders 
(4H leukodystrophy) 
  +/-    + + +/- +    Nystagmus 
18q minus syndrome 
  +/-    +        
X-Linked 
Adrenoleukodystrophy 
(X-ALD) 
   +   +  +     Adult onset cases with 
predominant myelopathy 
Adult onset 
leukodystrophy with 
neuroaxonal spheroids 
and pigmented glia 
(including hereditary 
diffuse 
leukoencephalopathy 
with spheroids, HDLS, 
and  Pigmentary type of 
orthochromatic 
leukodystrophy with 
pigmented glia, POLD) 
   +   + +      Frontotemporal dementia 
Aicardi-Goutières 
Syndrome (AGS) 
 + +  +  +  +      
Alexander Disease (AxD) 
+   +      +  + + Bulbar dysfunction in adult 
onset cases 
Nystagmus is prominent 
Adult onset autosomal 
dominant 
leukodystrophy (ADLD) 
      +    + +  Mixed lower and upper 
motor neuron disease 
Canavan Disease 
+  +  + + + +     + Nystagmus is prominent 
Patients may have 
sensorineural hearing loss 
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Cerebrotendinous 
Xanthomatosis (CTX) 
  + +   +   + +  +  
Chloride Ion Channel 
2(ClC-2) related 
leukoencephalopathy 
with intramyelinic 
oedema 
   +   +       Severe headache in some 
cases 
eIF2B related disorder 
(Vanishing WM Disease 
of CACH) 
      +   +    Acute neurologic 
deteriorations in the 
context of stressors 
Nystagmus is prominent 
Fucosidosis 
  +    + +       
Globoid Cell 
Leukodystrophy 
(Krabbe) 
  + + +  +  + + +  +  
Hypomyelination with 
atrophy of the basal 
ganglia and cerebellum 
(H-ABC) 
      + + + +     
Hypomyelination with 
Brainstem and Spinal 
Cord involvement and 
Leg Spasticity (HBSL)* 
      +  + +    May be steroid responsive 
Hypomyelination with 
congenital cataract 
(HCC) 
      +   + +    
Leukoencephalopathy 
with brainstem and 
spinal cord involvement 
and lactate elevation 
(LBSL) 
      +  + +     
Leukoencephalopathy 
with thalamus and 
brainstem involvement 
and high lactate (LTBL) 
  +/-    +   +   + May improve over time 
Megalencephalic 
Leukoencephalopathy 
with subcortical cysts 
+      +   +   + May improve over time 
Metachromatic 
Leukodystrophy and its 
biochemical variants 
  +/- +  + +   + +  +  
Oculodentodigital 
dysplasia 
  +    +   +   + Sensorineural hearing loss 
can be seen 
Pelizaeus Merzbacher 
disease (PMD) * 
      + + + + +
^
   Nystagmus is prominent 
Respiratory stridor is a 
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common feature in the 
connatal form. 
Neuropathy in PLP null 
syndrome. 
Pelizaeus Merzbacher 
like-disease (PMLD) * 
         + +   Nystagmus is prominent 
Peroxisomal Biogenesis 
disorders (including 
Zelleweger, neonatal 
Adrenoleukodystrophy 
and Infantile Refsum) 
  +   + +    +  +  
Polyglucosan Body 
Disease (PGBD) 
          + +   
RNAse T2 deficient 
leukoencephalopathy 
 + +/-    +       Deafness can be observed 
Sialic acid storage 
disorders (Salla disease, 
Infantile Sialic Acid 
Storage Disease and 
Intermediate form) 
  +   + +   +   +  
Single enzyme 
deficiencies of 
peroxisomal fatty acid 
beta oxidation ( 
including only D-
Bifunctional Protein 
Deficiency; SCPx 
deficiency ; Peroxisomal 
acyl-CoA-Oxidase 
Deficiency) 
  +   + +        
Sjögren-Larsson 
syndrome* 
  +    +  +    +/-  
SOX10-associated 
PCWH: peripheral 
demyelinating 
neuropathy, central 
dysmyelinating 
leukodystrophy, 
Waardenburg syndrome, 
and Hirschsprung 
disease 
      +   +    Deafness can be observed 
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Table 3. Extra-neurologic signs and symptoms in the leukodystrophies.  Systemic involvement is more commonly seen in the genetic 
leukoencephalopathies, but disorders that are not canonical leukodystrophies are not included in this table  
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Pol-III related 
disorders (4H 
leukodystrophy) 
+ + + +  +   +   +      +   
Hypogonadotrop
ic 
hypogonadism 
18q minus 
syndrome 
    +                
Genital 
abnormalities, 
congenital heart 
disease, 
immune 
manifestions 
and skin 
abnormalities 
may also be 
present 
X linked 
Adrenoleuko-
dystrophy* 
+       +             
 
Aicardi-
Goutières 
Syndrome 
(AGS) 
 + +        +     + +    
Rare patients 
may have a 
cardiomyopathy 
Retinal vascular 
abnormalities 
can be seen in 
certain patients 
with autosomal 
dominant 
TREX1 
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mutations 
(RVCL) 
Canavan 
disease*            +         
 
Cerebro-
tendinous 
Xanthomatosis 
(CTX) 
 
 +       +   +  +    + +  
Atherosclerosis 
Tendon 
xanthomas 
Neonatal 
cholestatic 
jaundice 
eIF2B related 
disorder 
(Vanishing WM 
Disease or 
CACH) 
 
        +          +  
Connatal onset 
may have 
ovarian 
dysgenesis 
Only connatal 
cases have 
cataracts 
Fucosidosis 
               +     
Facial 
coarsening ad 
cardiomegaly 
are also present 
Hypo-
myelination with 
congenital 
cataracts 
        +            
 
Metachromatic 
Leukodystrophy 
and its 
biochemical 
variants* 
              +      
 
Oculo-
dentodigital 
dysplasia 
    + +     + +     +    
Bony 
abnormalities 
involving the 
digits are seen, 
as well as cleft 
lip and palate  
Peroxisomal 
Biogenesis 
disorders 
(including 
Zelleweger, 
neonatal 
Adrenoleukodys
trophy and 
Infantile 
Refsum) 
+   + +  +  +   + + +  +  +  + 
Renal 
involvement, 
such as cysts, 
may be seen 
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Sialic acid 
storage 
disorders (Salla 
disease, 
Infantile Sialic 
Acid Storage 
Disease and 
Intermediate 
form) 
    +  +   +      + + +   
Facial 
coarsening 
Sjögren-
Larsson 
syndrome* 
   +   +              
Retinal 
“glistening” 
white dots can 
be seen in 
macular region 
 
^^ The following disorders classified as leukodystrophies do not have prominent extra-neurologic features and as such are not listed on this table. 
These include: Adult onset leukodystrophy with neuroaxonal spheroids and pigmented glia caused by mutations in CSF1R glia, POLD,  AxD, ADLD, 
ClC-2 related leukoencephalopathy with intramyelinic oedema, Krabbe, H-ABC, HBSL, HCC, LBSL, LTBL, Megalencephalic Leukodystrophy with 
subcortical cysts, Pelizaeus Merzbacher disease (PMD), Pelizaeus Merzbacher like-disease (PMLD), 
PGBD, RNAse T2 deficient leukoencephalopathy, Single enzyme deficiencies of peroxisomal fatty acid beta oxidation ( including only D-Bifunctional 
Protein Deficiency; SCPx deficiency ; Peroxisomal acyl-CoA-Oxidase Deficiency).
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Table 4: Treatable leukodystrophies.* 
  
Disease Screening test Treatment 
Adrenoleukodystrophy 
(cerebral) 
VLCFA Bone marrow transplantation 
in early stages of the 
disease. 
Cerebrotendinous 
Xanthomatosis 
Cholestanol Chenodeoxycholic acid; 
inhibitors of HMG-CoA 
reductase. 
Krabbe Galactocerebrosidase 
activity assay 
Bone marrow transplantation 
in pre-symptomatic and early 
symptomatic patients, 
though the benefit of this is 
still undergoing testing. 
Metachromatic 
leukodystrophy 
Arylsulfatase A 
activity assay 
Bone marrow transplantation 
in pre-symptomatic and early 
symptomatic patients though 
the benefit of this is still 
undergoing testing. 
 
*Note, this does not include the many genetic leukoencephalopathies, including but not limited 
to amino acidemias (MSUD, PKU, etc.), organic acidurias (MMA, IVA, PA, etc.), Niemann-Pick 
type C, biotinidase deficiency, Wilson’s disease, etc.
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Table 5: Minimum recommended gene list for broad spectrum genetic testing for single-
nucleotide variants associated with leukodystrophies and genetic leukoencephalopathies.  
 
Disease Name(s) OMIM  Gene(s) 
Hypomyelinating Leukodystrophies    
Pol-III related disorders (4H leukodystrophy) 607694 
 
POLR3A,  
POLR3B 
Hypomyelinating leukodystrophy 
Dystonia, type4 
HABC 
612438 TUBB4A 
Hypomyelination and congenital cataract (HCC)  610532 FAM126A 
Pelizaeus-Merzbacher disease (PMD) 312080 PLP1 
Hypomyelinating leukodystrophy 2 (HLD2) 
Pelizaeus-Merzbacher-like disease 1 (PMLD1) 
608804 
  
GJC2 
SOX10-associated PCWH: peripheral demyelinating neuropathy, 
central dysmyelinating leukodystrophy, Waardenburg syndrome, 
and Hirschsprung disease 
609136 SOX10 
Other Leukodystrophies  
X-linked Adrenoleukodystrophy (X-ALD) 300100 ABCD1 
Adult-onset leukodystrophy with neuroaxonal spheroids and 
pigmented glia (including Hereditary diffuse leukoencephalopathy 
with spheroids (HDLS) and Pigmentary orthochromatic 
leukodystrophy (POLD)) 
221820 CSF1R 
Aicardi-Goutières Syndrome (AGS) 
615010 
610333 
610181 
610329 
612952 
225750 
ADAR1, 
RNASEH2A, 
RNASEH2B, 
RNASEH2C, 
SAMHD1,  
TREX1 
Alexander disease (AxD) 203450 GFAP 
Adult onset autosomal dominant leukodystrophy (ADLD) 169500 LMNB1 
Canavan disease 271900 ASPA 
Cerebrotendinosus Xanthomatosis (CTX) 213700 CYP27A1 
Chloride Ion Channel 2(ClC-2) related leukoencephalopathy with 
intramyelinic oedema 
615651 CLCN2 
eIF2B related disorder (Vanishing WM Disease or CACH) 
603896 
603896 
603896 
603896 
603896 
EIF2B1, 
EIF2B2, 
EIF2B3, 
EIF2B4, 
EIF2B5 
Fucosidosis  230000 FUCA1 
Globoid cell leukodystrophy (Krabbe disease) 
245200 
611722 
GALC, 
PSAP 
Hypomyelination wit Brainstem and Spinal Cord Involvement and 
Leg Spasticity (HBSL) 
615281 DARS 
Leukoencephalopathy with brain stem and spinal cord involvement 
and lactate elevation (LBSL) 
611105 DARS2 
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Leukoencephalopathy with thalamus and brainstem involvement 
and high lactate (LTBL) 
NA EARS2 
Multiple sulfatase deficiency 272200 SUMF1 
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) 
604004 
 
613925 
MLC1,  
HEPACAM 
Metachromatic Leukodystrophy (MLD) 
607574 
249900 
ARSA,  
PSAP 
Oculodentodigital dysplasia (ODDD) 257850 GJA1 
Polyglucosan Body Disease (PGBD) 263570 GBE1 
RNAse T2 deficient leukoencephalopathy 612951 RNASET2 
Sialic acid storage disease 269920 SLC17A5 
Sjögren Larsson syndrome 270200 ALDH3A2 
Progressive leukoencephalopathy with ovarian failure 615889 AARS2 
Other Leukodystrophies: Peroxisomal biogenesis disorders  
Peroxisome biogenesis disorder 1A,B 214100, 
601539 
PEX1 
Peroxisome biogenesis disorder 5A,B 614866, 
614867 
PEX2 
Peroxisome biogenesis disorder 10A 614882 PEX3 
Peroxisome biogenesis disorder 4A,B 614862, 
614863 
PEX6 
Peroxisome biogenesis disorder 6A,B 614870, 
614871 
PEX10 
Peroxisome biogenesis disorder 3A,B 614859, 
266510 
PEX12 
Peroxisome biogenesis disorder 3A,B 614872, 
614873 
PEX26 
Other Leukodystrophies: Peroxisomal single enzyme beta oxidation deficiencies  
D-bifunctional protein deficiency 261515 
 
HSD17B4 
 
Sterol carrier protein 2 deficiency 
Leukoencephalopathy with dystonia and motor neuropathy 
613724 SCP2 
Peroxisomal acyl-coA-oxidase deficiency 264470 ACOX1 
Genetic Leukoencephalopathies  
L2-Hydroxyglutaric aciduria 
600721 
236792 
615182 
D2HGDH 
L2HGDH 
SLC25A1 
Cockayne syndrome; UV-sensitive syndrome 609412 ERCC6, 
ERCC8 
Deafness, dystonia, and cerebral hypomyelination 300475 BCAP31 
Trichothiodystrophy, nonphotosensitive 234050 MPLKIP 
Trichotiodystrophy with hypersensitivity to sunlight 601675 ERCC2,  
ERCC3,  
GTF2H5,  
Hypomyelinating leukodystrophy 3 260600 AIMP1 
Hypomyelinating leukodystrophy 4 
Mitochondrial HSP60 chaperonopathy 
612233 
 
HSP60 
Global cerebral hypomyelination 603667 SLC25A12 
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GM1-gangliosidosis 230500 GLB1 
GM2-gangliosidosis 
Tay-Sachs disease 
272800 HEXA 
Infantile neuronal ceroid lipofuscinosis 256730 PPT1 
Mucolipidosis IV 252650 MCLON1 
Nasu-Hakola disease 
Dementia with bone cysts 
221770 TYROBP 
Phosphoglycerate dehydrogenase deficiency 601815 PHGDH 
Phosphoserine aminotransferase deficiency 610992 
 
PSAT1 
 
Allan-Herndon-Dudley syndrome 
Monocarboxylate transporter 8 deficiency (MCT8) 
300523 
 
SLC16A2 
Band-like intracranial calcification with simplified gyration and 
polymicrogyria 
251290 
 
OCLN 
 
Cerebral arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) 
125310 
 
NOTCH3 
 
Cerebral autosomal recessive arteriopathy with subcortical infarcts 
and leukoencephalopathy (CARASIL) 
600142 
 
HTRA1 
 
Hereditary angiopathy with neuropathy, aneurysms and muscle 
cramps 
611773 
 
COL4A1 
 
Wilson disease 277900 ATP7B 
Menkes disease 300011 ATP7A 
Leukodystrophy, hypomyelinating, 4 
Spastic Paraplegia 13 
612233 
605280 
HSPD1 
Fabry disease 301500 GLA 
Familial hemophagocytic lymphohistiocytosis 5 613101 STXBP2 
Familial hemophagocytic lymphohistiocytosis 3 608898 UNC13D 
Familial hemophagocytic lymphohistiocytosis 4 603552 STX11 
Familial hemophagocytic lymphohistiocytosis 2 603553 PRF1 
Lowe syndrome  309000 OCRL 
Niemann-Pick type C2 601015 NPC2 
Niemann-Pick type C1 257220 NPC1 
Genetic Leukoencephalopathies: Mitochondrial Disorders  
Mitochondrial complex I disorders 252010 NDUFS1, NDUFS4, 
NDUFS7, NDUFS8, 
NDUFV1, NDUFS2, 
NDUFAF1 
Mitochondrial complex II disorders 252011 SDHA,  
SDHB, 
SDHAF1, 
Mitochondrial complex III disorders 124000 BCS1L 
Mitochondrial complex IV disorders 256000 
603644 
604377 
220110 
256000 
220110 
SURF1, 
SCO1, 
SCO2, 
COX10, 
COX15, 
TACO1 
Mitochondrial complex V disorders 220110 ATPAF2 
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Glutaric Acidemia IIC 231680 ETFDH 
Coenzyme Q10 deficiency, primary, 4 612016 ADCK3 
Combined oxidative phosphorylation deficiency 1 609060 GFM1 
Combined oxidative phosphorylation deficiency 2 610498 MRPS16 
Combined oxidative phosphorylation deficiency 4 610678 TUFM 
Mitochondrial DNA depletion syndrome 4A, 4B and recessive ataxia 
syndrome  
203700 
613662 
607459 
POLG 
Progressive external ophthalmoplegia with mitochondrial DNA 
deletions 
610131 POLG2 
Mitochondrial DNA depletion syndrome 1 603041 TYMP 
Mitochondrial DNA depletion syndrome 5  612073 SUCLA2 
Mitochondrial DNA depletion syndrome 7 271245 C10ORF2 
Mitochondrial DNA depletion syndrome 8A 604712 RRM2B 
Mitochondrial DNA depletion syndrome 12  615418 SLC25A4 
Coenzyme Q10 deficiency, primary, 1 607426 COQ2 
Coenzyme Q10 deficiency, primary, 5 614654 COQ9 
Mitochondrial DNA depletion syndrome 3 251880 DGUOK 
Genetic Leukoencephalopathies: Hereditary Spastic Paraplegias  
Spastic paraplegia 4 (SPG4) 182601 SPAST 
Spastic paraplegia 5 (SPG5) 270800 CYP7B1 
Spastic paraplegia 7 (SPG7) 607259 SPG7 
Spastic paraplegia 11 (SPG11) 604360 SPG11 
Spastic paraplegia 15 (SPG15) 270700 ZFYVE26 
Spastic paraplegia 20 (SPG20) 275900 SPG20 
Spastic paraplegia 21 (SPG21) 248900 ACP33 
Spastic paraplegia 35 (SPG35) 612319 FA2H 
Spastic paraplegia 56 (SPG56) 615030 CYP2U1 
** 18q minus syndrome recommendations 
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Table 6. Clinical and Laboratory tests that aid in the diagnosis of LDs and gLEs  
 
Clinical/Laboratory Test* Diagnostic Target 
Brain and spinal MRI (± gadolinium, ± MRS) Establish white matter disease; ±  evidence of 
leaky blood brain barrier and metabolite 
accumulation (mitochondrial disorders, 
Canavan, Sjögren Larsson Syndrome, 
peroxisomal biogenesis disorders) 
Ophthalmologic exam Document ophthalmologic signs in several 
leukodystrophies 
Head CT  Assess for calcifications 
Plasma very long-chain fatty acids X-ALD/AMN and peroxisomal biogenesis 
disorders 
Lysosomal  enzymes (leukocytes) Metachromatic Leukodystrophy, Krabbe, 
Multiple sulfatase deficiency, 
Galactosialidosis, Sialidosis 
Blood Lactate, pyruvate, amino acids Mitochondrial disorders 
Lumbar Puncture (cell count, protein, ± CSF 
neopterin, ± interferon-alpha) 
Non-specific marker of demyelination;  
± pleocytosis and AGS markers 
Urine sulfatides  MLD, Multiple sulfatase deficiency 
 
Urine organic acids L-2-hydroxyglutarate; NAA for Canavan 
disease; Krebs cycle intermediates 
(mitochondrial disorders) 
Neurophysiologic studies (BAER, EMG/NCV, 
VEP, SSEP) 
Characterize involvement of cranial and 
peripheral nerves, optic tracts and spinal 
tracts 
Genetic analyses As indicated for each LD or gLE 
 
* Additional tests may be indicated for patients with certain distinctive clinical presentations or 
extra-neurologic features suggestive of one or more specific leukodystrophies. 
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13. Figure Legends 
 
Figure 1. Recommended molecular diagnostic workflow. Note emphasis on identification of 
treatable disorders to enable rapid changes in care as appropriate. For a complete description 
of this figure please see the main text. Abbreviations: P = pathogenic; LP = likely pathogenic. 
 
Figure 2. MRI pattern recognition in the LD and gLE (reprinted with permission from 
Genereviews). Three major MRI characteristics help to discriminate between the different types 
of LD and gLE. The first discriminator is the presence or absence of hypomyelination (Figure 
2a). Within this subset, the presence of improvement of myelination or atrophy directs the 
clinician towards a series of gLEs. Within the true hypomyelinating LDs, the presence of basal 
ganglia and cerebellar involvement further helps refine the diagnosis. If the pattern is not one of 
hypomyelination, then the second discriminator is whether the white matter abnormalities are 
confluent or isolated and multifocal (Figure 2b). If the white matter abnormalities are confluent, 
then the third discriminator is the predominant localization of the abnormalities (Figure 2b). 
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Highlights 
 
If accepted, we propose the following highlights: 
 Leukodystrophies are genetic disorders affecting the white matter of the central 
nervous system with or without peripheral nervous system involvement 
 Although individual features may vary, leukodystrophies and genetic 
leukoencephalopathies all share white matter abnormalities on imaging or 
pathology of the CNS, and most have motor deficits that often dominate the 
clinical picture, especially in pediatric patients 
 Brain MRI is the foundational investigation in a patient with a suspected 
leukodystrophy or genetic leukoencephalopathy 
 The number of disorders with established therapies is small in number and as 
such these disorders require prompt recognition and downstream testing 
 The partnering of MRI pattern analysis and next-generation sequencing may lead 
to higher diagnostic yield and more timely diagnosis 
